Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients

Frontiers in Oncology

Volumn 4, Issue OCT, 2014, Pages

  Tian, Sibo ^a   Hirshfield, Kim M ^a   Jabbour, Salma K ^a   Toppmeyer, Deborah ^a   Haffty, Bruce G ^a   Khan, Atif J ^a   Goyal, Sharad ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Breast cancer; Cardiac biomarkers; Cardiotoxicity; Chemotherapy; Radiation therapy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOP; DOXORUBICIN; EPIRUBICIN; FATTY ACID BINDING PROTEIN; FLUORODEOXYGLUCOSE; GALECTIN 3; GLYCOGEN PHOSPHORYLASE ISOENZYME BB; GLYCOSYLTRANSFERASE; GROWTH DIFFERENTIATION FACTOR; LAPATINIB; MYELOPEROXIDASE; NERATINIB; NITRIC OXIDE; PERTUZUMAB; PLACENTAL GROWTH FACTOR; RAZOXANE; SOLUBLE FMS LIKE TYROSINE KINASE RECEPTOR 1; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TROPONIN I; TROPONIN T; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

BLOOD LEVEL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; NONHUMAN; RADIATION INJURY; REVIEW;

EID: 84907750721     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00277     Document Type: Review

References (132)

1. Centers for Disease Control. Prevention. Cancer survivors - United States, 2007. MMWR Morb Mortal Wkly Rep (2011) 60(9):269-72.
2. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol (2008) 130(5):688-95. doi: 10.1309/AJCPB66LRIIVMQDR
3. Germanakis I, Anagnostatou N, Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer (2008) 51(3):327-33. doi:10.1002/pbc.21633
4. Mavinkurve-Groothuis AM, Kapusta L, Nir A, Groot-Loonen J. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol (2008) 25(7):655-64. doi:10.1080/08880010802244001
5. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis (2010) 53(2):121-9. doi:10.1016/j.pcad.2010.04.002
6. Cardinale D, Salvatici M, Sandri MT. Role of biomarkers in cardioncology. Clin Chem Lab Med (2011) 49(12):1937-48. doi:10.1515/CCLM.2011.692
7. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 365(9472):1687-717. doi:10.1016/S0140-6736(05)66544-0
8. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med (1996) 125(1):47-58. doi:10.7326/0003-4819-125-1-199607010-00008
9. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol (2008) 26(22):3777-84. doi:10.1200/JCO.2007.14.9401
10. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev (2004) 56(2):185-229. doi:10.1124/pr.56.2.6
11. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf (2000) 22(4):263-302. doi:10.2165/00002018-200022040-00002
12. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer (2010) 10:337. doi:10.1186/1471-2407-10-337
13. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 62(2):200-8. doi:10.1016/0002-9343(77)90315-1
14. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA (1991) 266(12):1672-7. doi:10.1001/jama.266.12.1672
15. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 324(12):808-15. doi:10.1056/NEJM199103213241205
16. Goldberg JM, Scully RE, Sallan SE, Lipshultz SE. Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol (2012) 34(5):395-7. doi:10.1097/MPH.0b013e3182532078
17. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst (2008) 100(19):1368-79. doi:10.1093/jnci/djn310
18. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med (2006) 355(15):1572-82. doi:10.1056/NEJMsa060185
19. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-82. doi:10.1126/science.3798106
20. Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol (2010) 21(11):2153-60. doi:10.1093/annonc/mdq096
21. Chien AJ, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf (2010) 9(2):335-46. doi:10.1517/14740331003627441
22. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol (2004) 22(6):1063-70. doi:10.1200/JCO.2004.06.557
23. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol (2005) 23(31):7820-6. doi:10.1200/JCO.2005.13.300
24. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 25(25):3859-65. doi:10.1200/JCO.2006.09.1611
25. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol (2002) 20(5):1215-21. doi:10.1200/JCO.20.5.1215
26. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet (2012) 379(9816):633-40. doi:10.1016/S0140-6736(11)61847-3
27. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2012) 366(2):109-19. doi:10.1056/NEJMoa1113216
28. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol (2012) 30(21):2585-92. doi:10.1200/JCO.2011.35.6725
29. Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol (2011) 29(4):398-405. doi:10.1200/JCO.2010.29.5865
30. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2010) 28(8):1301-7. doi:10.1200/JCO.2009.25.8707
31. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 13(1):25-32. doi:10.1016/S1470-2045(11)70336-9
32. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol (2013) 31(9):1157-63. doi:10.1200/JCO.2012.44.9694
33. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol (2012) 30(26):3234-41. doi:10.1200/JCO.2011.40.5902
34. Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 14(12):1183-92. doi:10.1016/S1470-2045(13)70411-X
35. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 366(9503):2087-106. doi:10.1016/S0140-6736(05)67887-7
36. Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol (1994) 12(3):447-53.
37. Senkus-Konefka E, Jassem J. Cardiovascular effects of breast cancer radiotherapy. Cancer Treat Rev (2007) 33(6):578-93. doi:10.1016/j.ctrv.2007.07.011
38. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol (2005) 6(8):557-65. doi:10.1016/S1470-2045(05)70251-5
39. Gagliardi G, Constine LS, Moiseenko V, Correa C, Pierce LJ, Allen AM, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys (2010) 76(3 Suppl):S77-85. doi:10.1016/j.ijrobp.2009.04.093
40. Shapiro CL, Hardenbergh PH, Gelman R, Blanks D, Hauptman P, Recht A, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol (1998) 16(11):3493-501.
41. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 91(5):710-7. doi:10.7326/0003-4819-91-5-710
42. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol (2009) 27(16):2638-44. doi:10.1200/JCO.2008.17.9549
43. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst (2005) 97(6):419-24. doi:10.1093/jnci/dji067
44. Patt DA, Goodwin JS, Kuo YF, Freeman JL, Zhang DD, Buchholz TA, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol (2005) 23(30):7475-82. doi:10.1200/JCO.2005.13.755
45. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. J Am Coll Cardiol (2007) 50(19):1914-31. doi:10.1016/j.jacc.2007.09.008
46. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol (2009) 10(4):391-9. doi:10.1016/S1470-2045(09)70042-7
47. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol (2003) 10(2):132-9. doi:10.1067/mnc.2003.7
48. Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol (2010) 28(21):3429-36. doi:10.1200/JCO.2009.26.7294
49. Ganame J, Claus P, Uyttebroeck A, Renard M, D'Hooge J, Bijnens B, et al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr (2007) 20(12):1351-8. doi:10.1016/j.echo.2007.04.007
50. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol (2012) 30(23):2876-84. doi:10.1200/JCO.2011.40.3584
51. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol (2011) 57(22):2263-70. doi:10.1016/j.jacc.2010.11.063
52. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer (2003) 97(11):2869-79. doi:10.1002/cncr.11407
53. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol (2002) 13(5):699-709. doi:10.1093/annonc/mdf132
54. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. Can Med Associat J (2005) 173(10):1191-202. doi:10.1503/cmaj/051291
55. O'Brien PJ. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology (2008) 245(3):206-18. doi:10.1016/j.tox.2007.12.006
56. Adamcova M, Sterba M, Simunek T, Potacova A, Popelova O, Mazurova Y, et al. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf (2005) 4(3):457-72. doi:10.1517/14740338.4.3.457
57. Jensen JK, Atar D, Mickley H. Mechanism of troponin elevations in patients with acute ischemic stroke. Am J Cardiol (2007) 99(6):867-70. doi:10.1016/j.amjcard.2006.07.071
58. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J (2004) 25(14):1187-96. doi:10.1016/j.ehj.2004.04.026
59. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol (1999) 17(7):2237-43.
60. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol (2000) 36(2):517-22. doi:10.1016/S0735-1097(00)00748-8
61. Cardinale D. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol (2002) 13(5):710-5. doi:10.1093/annonc/mdf170
62. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation (2004) 109(22):2749-54. doi:10.1161/01.CIR.0000130926.51766.CC
63. Sandri MT, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem (2003) 49(2):248-52. doi:10.1373/49.2.248
64. Hughes-Davies L, Sacks D, Rescigno J, Howard S, Harris J. Serum cardiac troponin T levels during treatment of early-stagebreast cancer. J Clin Oncol (1995) 13(10):2582-4.
65. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation (1997) 96(8):2641-8. doi:10.1161/01.CIR.96.8.2641
66. Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol (2003) 82(4):218-22. doi:10.1007/s00277-003-0615-3
67. Kismet E, Varan A, Ayabakan C, Alehan D, Portakal O, Buyukpamukcu M. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer (2004) 42(3):220-4. doi:10.1002/pbc.10368
68. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med (2004) 351(2):145-53. doi:10.1056/NEJMoa035153
69. Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol (2005) 16(5):798-804. doi:10.1093/annonc/mdi152
70. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol (2006) 24(15):2276-82. doi:10.1200/JCO.2005.03.8448
71. Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol (2008) 97(5):318-26. doi:10.1007/s00392-007-0633-6
72. Kozak KR, Hong TS, Sluss PM, Lewandrowski EL, Aleryani SL, Macdonald SM, et al. Cardiac blood biomarkers in patients receiving thoracic (chemo)radiation. Lung Cancer (2008) 62(3):351-5. doi:10.1016/j.lungcan.2008.03.024
73. Cil T, Kaplan AM, Altintas A, Akin AM, Alan S, Isikdogan A. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin Drug Investig (2009) 29(2):131-7. doi:10.2165/0044011-200929020-00007
74. Mavinkurve-Groothuis AM, Groot-Loonen J, Bellersen L, Pourier MS, Feuth T, Bökkerink JP, et al. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr Blood Cancer (2009) 52(5):631-6. doi:10.1002/pbc.21913
75. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol (2010) 28(25):3910-6. doi:10.1200/JCO.2009.27.3615
76. Nellessen U, Zingel M, Hecker H, Bahnsen J, Borschke D. Effects of radiation therapy on myocardial cell integrity and pump function: which role for cardiac biomarkers? Chemotherapy (2010) 56(2):147-52. doi:10.1159/000313528
77. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol (2011) 148(2):194-8. doi:10.1016/j.ijcard.2009.09.564
78. Goel S, Simes RJ, Beith JM. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. Asia Pac J Clin Oncol (2011) 7(3):276-80. doi:10.1111/j.1743-7563.2011.01422.x
79. Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res (2011) 17(10):3490-9. doi:10.1158/1078-0432.CCR-10-1359
80. Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M, et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer (2011) 105(11):1663-8. doi:10.1038/bjc.2011.439
81. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol (2011) 107(9):1375-80. doi:10.1016/j.amjcard.2011.01.006
82. D'Errico MP, Grimaldi L, Petruzzelli MF, Gianicolo EA, Tramacere F, Monetti A, et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys (2012) 82(2):e239-46. doi:10.1016/j.ijrobp.2011.03.058
83. Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M, et al. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis. Cardiovasc Toxicol (2012) 12(2):135-42. doi:10.1007/s12012-011-9149-4
84. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol (2012) 30(10):1042-9. doi:10.1200/JCO.2010.30.3404
85. Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat (2012) 134(1):291-8. doi:10.1007/s10549-012-2039-z
86. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circul Cardiovasc Imag (2012) 5(5):596-603. doi:10.1161/CIRCIMAGING.112.973321
87. Sherief LM, Kamal AG, Khalek EA, Kamal NM, Soliman AA, Esh AM. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. Hematology (2012) 17(3):151-6. doi:10.1179/102453312X13376952196412
88. Erven K, Florian A, Slagmolen P, Sweldens C, Jurcut R, Wildiers H, et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys (2013) 85(5):1172-8. doi:10.1016/j.ijrobp.2012.09.022
89. Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol (2014) 63(8):809-16. doi:10.1016/j.jacc.2013.10.061
90. Pongprot Y, Sittiwangkul R, Charoenkwan P, Silvilairat S. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer. J Pediatr Hematol Oncol (2012) 34(8):589-95. doi:10.1097/MPH.0b013e31826faf44
91. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol (1998) 274(1 Pt 2):F63-72.
92. Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, et al. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol (2008) 102(6):733-7. doi:10.1016/j.amjcard.2008.04.048
93. Masson S, Latini R. Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure. Am J Cardiol (2008) 101(3A):56-60. doi:10.1016/j.amjcard.2007.11.024
94. Yu CM, Sanderson JE, Shum IO, Chan S, Yeung LY, Hung YT, et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J (1996) 17(11):1694-702. doi:10.1093/oxfordjournals.eurheartj.a014753
95. Selvais PL, Donckier JE, Robert A, Laloux O, van Linden F, Ahn S, et al. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. Eur J Clin Invest (1998) 28(8):636-42. doi:10.1046/j.1365-2362.1998.00338.x
96. ElGhandour AH, El Sorady M, Azab S, ElRahman M. Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. Hematol Rep (2009) 1:1. doi:10.4081/hr.2009.e6
97. Kouloubinis A, Kaklamanis L, Ziras N, Sofroniadou S, Makaritsis K, Adamopoulos S, et al. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. Int J Cardiol (2007) 122(3):195-201. doi:10.1016/j.ijcard.2006.11.076
98. Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van denBerg MP, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol (2001) 19(10):2746-53.
99. Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med (2002) 251(3):228-34. doi:10.1046/j.1365-2796.2002.00951.x
100. Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Failure (2005) 7(1):87-93. doi:10.1016/j.ejheart.2004.03.009
101. Perik PJ, De Vries EG, Boomsma F, van der Graaf WT, Sleijfer DT, van Veldhuisen DJ, et al. Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors. Anticancer Res (2005) 25(5):3651-7.
102. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem (2005) 51(8):1405-10. doi:10.1373/clinchem.2005.050153
103. Germanakis I, Kalmanti M, Parthenakis F, Nikitovic D, Stiakaki E, Patrianakos A, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol (2006) 108(2):212-5. doi:10.1016/j.ijcard.2005.05.006
104. Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L'Ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer (2007) 49(6):812-6. doi:10.1002/pbc.21100
105. Ekstein S, Nir A, Rein AJ, Perles Z, Bar-Oz B, Salpeter L, et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol (2007) 29(7):440-4. doi:10.1097/MPH.0b013e3180640d42
106. Jingu K, Nemoto K, Kaneta T, Oikawa M, Ogawa Y, Ariga H, et al. Temporal change in brain natriuretic Peptide after radiotherapy for thoracic esophageal cancer. Int J Radiat Oncol Biol Phys (2007) 69(5):1417-23. doi:10.1016/j.ijrobp.2007.05.054
107. Albers S, Mir TS, Haddad M, Laer SN. Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin Chem Lab Med (2006) 44(1):80-5. doi:10.1515/CCLM.2006.016
108. Mladosievicova B, Urbanova D, Radvanska E, Slavkovsky P, Simkova I. Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines. J Exp Clin Cancer Res (2012) 31:86. doi:10.1186/1756-9966-31-86
109. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol (2009) 30(1):3-8. doi:10.1007/s00246-008-9258-4
110. Kittiwarawut A, Vorasettakarnkij Y, Tanasanvimon S, Manasnayakorn S, Sriuranpong V. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction. Asia Pac J Clin Oncol (2013) 9(2):155-61. doi:10.1111/j.1743-7563.2012.01588.x
111. O'Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation (2006) 114(6):550-7. doi:10.1161/CIRCULATIONAHA.106.641936
112. Glatz JF, van der Vusse GJ, Simoons ML, Kragten JA, van Dieijen-Visser MP, Hermens WT. Fatty acid-binding protein and the early detection of acute myocardial infarction. Clin Chim Acta (1998) 272(1):87-92. doi:10.1016/S0009-8981(97)00255-6
113. Azzazy HM, Pelsers MM, Christenson RH. Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem (2006) 52(1):19-29. doi:10.1373/clinchem.2005.056143
114. Horacek JM, Jebavy L, Ulrychova M, Tichy M, Pudil R, Zak P, et al. Glycogen phosphorylase BB could be a new biomarker for detection of cardiac toxicity during hematopoietic cell transplantation for hematological malignancies. Bone Marrow Transplant (2010) 45(6):1123-4. doi:10.1038/bmt.2009.306
115. Horacek JM, Tichy M, Pudil R, Jebavy L. Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity. Ann Oncol (2008) 19(9):1656-7. doi:10.1093/annonc/mdn414
116. Horacek JM, Vasatova M, Tichy M, Pudil R, Jebavy L, Maly J. The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. Exp Oncol (2010) 32(2):97-9.
117. Arruda-Olson AM, Enriquez-Sarano M, Bursi F, Weston SA, Jaffe AS, Killian JM, et al. Left ventricular function and C-reactive protein levels in acute myocardial infarction. Am J Cardiol (2010) 105(7):917-21. doi:10.1016/j.amjcard.2009.11.025
118. Arroyo-Espliguero R, Avanzas P, Quiles J, Kaski JC. Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis (2009) 204(1):239-43. doi:10.1016/j.atherosclerosis.2008.08.009
119. Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JG. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J (2007) 153(6):1048-55. doi:10.1016/j.ahj.2007.03.044
120. Lipshultz SE, Landy DC, Lopez-Mitnik G, Lipsitz SR, Hinkle AS, Constine LS, et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol (2012) 30(10):1050-7. doi:10.1200/JCO.2010.33.7907
121. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation (2003) 108(12):1440-5. doi:10.1161/01.CIR.0000090690.67322.51
122. Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol (2007) 49(24):2364-70. doi:10.1016/j.jacc.2007.02.053
123. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 43(2):109-42.
124. Haywood GA, Tsao PS, von derLeyen HE, Mann MJ, Keeling PJ, Trindade PT, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation (1996) 93(6):1087-94. doi:10.1161/01.CIR.93.6.1087
125. Winlaw DS, Smythe GA, Keogh AM, Schyvens CG, Spratt PM, Macdonald PS. Increased nitric oxide production in heart failure. Lancet (1994) 344(8919):373-4. doi:10.1016/S0140-6736(94)91403-6
126. Kalivendi SV, Kotamraju S, Zhao H, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem (2001) 276(50):47266-76. doi:10.1074/jbc.M106829200
127. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virág L, et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation (2003) 107(6):896-904. doi:10.1161/01.CIR.0000048192.52098.DD
128. Guler E, Baspinar O, Cekmen M, Kilinc M, Balat A. Nitric oxide: a new biomarker of Doxorubicin toxicity in children? Pediatr Hematol Oncol (2011) 28(5):395-402. doi:10.3109/08880018.2011.563373
129. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam (1968) 65(4):281-93.
130. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation (2006) 114(23):2474-81. doi:10.1161/CIRCULATIONAHA.106.635144
131. Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol (2013) 167(5):2306-10. doi:10.1016/j.ijcard.2012.06.023
132. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol (2006) 48(11):2258-62. doi:10.1016/j.jacc.2006.07.052